Some studies reported that Hsp90 inhibition in combination with ibrutinib may be an option for initial treatment in CLL to prevent the outgrowth of a resistant clone in patients [41]. The gene discussed is HSP90AB1; the disease is B-cell chronic lymphocytic leukemia.